Summary of change from baseline in the ACR core set measures at Week 104 (intent-to-treat population).

SJC, 66 Joint CountTJC, 68 Joint CountPatient Global VAS, mmPhysician Global VAS, mmPatient Pain VAS, mmCRP, mg/dlESR, mm/hHAQ-DI
Placebo-MTX, n = 393
  Minimum-maximum−58 to 43−65 to 42−89 to 29−87 to 25−78 to 45−14.927 to 1.150−108 to 30−2.3 to 1.4
4 mg/kg tocilizumab-MTX, n = 399
  Minimum-maximum−57 to 21−68 to 35−100 to 60−94 to 22−100 to 36−12.240 to 5.140−117 to 55−3.0 to 1.1
8 mg/kg tocilizumab-MTX, n = 398
  Minimum-maximum−62 to 48−67 to 48−95 to 39−97 to 48−96 to 34−19.281 to 3.359−114 to 57−2.9 to 1.5
  • Last-observation-carried-forward was used for TJC and SJC; no imputation was used for missing HAQ score, CRP, ESR, and VAS assessments. All assessments were set to missing from the time a patient receives escape therapy, and only pre-escape therapy joint count assessments were carried forward. CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire Disability Index; SJC: swollen joint count; TJC: tender joint count; VAS: visual analog scale; ACR: American College of Rheumatology; MTX: methotrexate.